Original Paper
The Autophagy Protein LC3A Correlates with Hypoxia and is a Prognostic Marker of Patient Survival in Clear Cell Ovarian Cancer
Issue
Monday, August 27, 2012
Sunday, August 26, 2012
Ann_Oncology - Preoperative PET/CT in early-stage breast cancer
Preoperative PET/CT in early-stage breast cancer
Abstract
Background The aim of this study was to assess the diagnostic and therapeutic impact of preoperative positron emission tomography and computed tomography (PET/CT) in the initial staging of patients with early-stage breast cancer.
Patients and methods A total of 103 consecutive patients with newly diagnosed operable breast cancer with tumors ≥2 cm were independently examined preoperatively with conventional assessment (mammography, breast/axillary ultrasound, chest X-ray and blood samples) and PET/CT with no prior knowledge of the other.
Results PET/CT identified a primary tumor in all but three patients (97%). PET/CT solely detected distant metastases (ovary, bones and lung) in 6 patients and new primary cancers (ovary, lung) in another two patients, as well as 12 cases of extra-axillary lymph node involvement. In 15 patients (15%), extra-axillary malignancy was detected by PET/CT only, leading to an upgrade of initial staging in 14% (14/103) and ultimately a modification of planned treatment in 8% (8/103) of patients.......,
Sent from my iPhone
Saturday, August 25, 2012
Clinical Oncology News - The Paradox of Increased Efficacy and End-of-Life Care
Clinical Oncology News - The Paradox of Increased Efficacy and End-of-Life Care
This commentary focuses on the complex and often emotionally charged conflict between a patient’s desire to “fight the cancer” and his or her unquestionably valid need to focus on end-of-life issues at some point in time.
Clinical Oncology News - Randomized Phase II trials: A Pragmatic Way To Inform Clinical Practice
Clinical Oncology News - Randomized Phase II trials: A Pragmatic Way To Inform Clinical Practice
.....
Consider, for example, the recent report on the biological activity of single-agent, nanoparticle albumin-bound paclitaxel in the second-line treatment of epithelial ovarian cancer.1 This nonrandomized study, conducted by the Gynecologic Oncology Group, revealed an objective response rate of 23%, similar to that previously reported with the far less expensive generic paclitaxel.2,3
But is it possible that this agent is actually superior to paclitaxel in that treatment with nanoparticle albumin-bound paclitaxel achieves a similar degree of objective clinical benefit (e.g., degree of tumor shrinkage and delay in time to progression) but with a measurably more favorable toxicity profile that includes a substantially reduced risk for peripheral neuropathy?
Unfortunately, in the complete absence of data from a randomized trial, the answer to this specific question will simply be unknown because any suggested “superior” outcomes may solely reflect the inadvertent selection bias resulting from the favorable baseline clinical features inherent in all nonrandomized studies........
Ten-Year Relative Survival for Epithelial ovarian cancer
Ten-Year Relative Survival for Epithelial Ovarian Cancer Gynecol. 2012 Sep;120(3):612-618.
OBJECTIVE: Most patients with epithelial ovarian cancer who are alive at 5 years have active disease. Thus, 10-year survival rather than 5-year survival may be a more appropriate endpoint. Relative survival adjusts for the general survival of the United States population for that race, sex, age, and date at which the diagnosis was coded. Our objective was to estimate relative survival in epithelial ovarian cancer over the course of 10 years.
METHODS: Using the Surveillance, Epidemiology and End Results 1995-2007 database, epithelial ovarian cancer cases were identified. Using the actuarial life table method, relative survival over the course of 10 years was calculated, stratified by stage, classification of residence, surgery as the first course of treatment, race, and age.
RESULTS: There were 40,692 patients who met inclusion criteria. The overall relative survival was 65%, 44%, and 36% at 2, 5, and 10 years, respectively. The slope of decline in relative survival was reduced for years 5-10 as compared with years 1-5 after diagnosis. Relative survival at 5 years was 89%, 70%, 36%, and 17%, and at 10 years relative survival was 84%, 59%, 23%, and 8% for stages I, II III, and IV, respectively. At all stages, patients with nonsurgical primary treatment and those with advanced age had reduced relative survival.
CONCLUSIONS: The 10-year relative survival for stage III is higher than expected. This information provides the physician and the patient with more accurate prognostic information.
Sent from my iPhone
FDA MedWatch - CareFusion Alaris Pump Module Model 8100: Class I Recall - Motor Stalls During Infusion
From: "U.S. Food & Drug Administration (FDA)" <fda@service.govdelivery.com>
Date: 25 August, 2012 8:42:31 AM EDT
Subject: U.S. Food & Drug Administration (FDA) Daily Digest Bulletin
Subject: FDA MedWatch - CareFusion Alaris Pump Module Model 8100: Class I Recall - Motor Stalls During Infusion
Friday, August 24, 2012
Detection of urothelial tumors: comparison of urothelial phase with excretory phase CT urography--a prospective study.
Detection of urothelial tumors: comparison of urothelial phase with excretory phase CT urography--a prospective study.
Sent from my iPhone
Thursday, August 23, 2012
ScienceDirect.com - European Journal of Cancer - Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials
Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials
Sent from my iPhone
Safety Alerts for Human Medical Products > CareFusion 303, Alaris Pump Module, Model 8100: Class I Recall - Potential for Pump Malfunction To Stop Infusion
...BACKGROUND: The pump module is intended for healthcare facilities that use infusion for the delivery of fluids, drugs, blood, and blood products using continuous or intermittent delivery through intravenous, intra-arterial, subcutaneous, epidural, enteral, or irrigation of fluid spaces routes of administration. The pump module is used for adults, children, and newborns...
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm316637.htm?source=govdelivery
Sent from my iPhone
Search Ovarian cancer: role of ultrasound in preoperative diagnosis and population screening.
Ovarian cancer: role of ultrasound in preoperative diagnosis and population screening.
Sent from my iPhone
Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).
Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).
Sent from my iPhone
Blog: truth, hope and communication...
....,Patients want us to be truthful, compassionate, and clear about their prognosis and want to know that we will be there with them every step of the way. Rather than taking away hope, being honest with our patients provides them with the necessary information to help them redefine hope, even if cure is not possible.
http://www.google.ca/reader/i/?source=mog&hl=en&gl=ca
Sent from my iPhone
Ovarian cancer study to look at lifestyle | The Australian
....More than 1000 newly diagnosed Australian women will participate in the five-year study.
"We are trying to answer the question that almost every woman with ovarian cancer asks - what can I do to help beat this disease?" said Associate Professor Penny Webb from the institute's gynaecological cancers group.....
http://m.theaustralian.com.au/news/breaking-news/ovarian-cancer-study-to-look-at-lifestyle/story-fn3dxiwe-1226456389727
Sent from my iPhone
LRP1B Deletion in High-Grade Serous Ova - PubMed Mobile
LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin.
Wednesday, August 22, 2012
Subscribe to:
Posts
(
Atom
)
